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ABSTRACT 
Keratoconjunctivitis sicca (KCS), also known as dry-eye disease, causes a deficiency of 
tears in both humans and canines.  Due to the lack of effective therapeutics for the treatment of 
dry-eye disease, there is a market potential for a novel secretion enhancing factor.  Lacritin, a 
naturally occurring tear glycoprotein, increases basal tearing in rabbits when topically applied to 
the ocular surface and shows potential as a dry-eye therapeutic.  This study aims to characterize 
Lacritin as a biomarker of dry-eye disease in canines with KCS. A total of 46 canine tear 
samples, 24 normal and 22 diagnosed with KCS, were obtained through a collaboration with the 
Virginia-Maryland College of Veterinarian Medicine and transported to James Madison 
University (JMU) for analysis.  A bicinchoninic acid assay (BCA) was used to determine total 
tear protein in the samples.  An indirect enzyme-linked immunosorbent assay (ELISA) was then 
used to determine the total tear Lacritin concentration in each sample using previously cloned 
and purified canine Lacritin as a standard.  Total tear protein of the samples was normalized and 
the proteins were separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE).  Western blot analysis with canine Lacritin antibodies was used to visualize 
Lacritin proteins and densitometry was used to determine the amount of the active Lacritin 
monomer (~18 kDa) band present. This study demonstrated that dry-eye samples had a 
significantly higher total protein concentration than normal samples, but a significantly lower 
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relative intensity of the monomeric Lacritin band than normal samples. There was no significant 
difference in total Lacritin concentration between dry-eye and normal canines, as determined by 
the ELISA. Thus, the lower relative intensity of monomeric Lacritin present in canines with dry-
eye suggests that monomeric Lacritin has potential as a biomarker of KCS, and should 
researched further in the future.  
 
INTRODUCTION 
Background 
 Keratoconjunctivitis Sicca (KCS) is a prevalent ocular disease also known as dry eye 
syndrome.  It occurs in both human and canine populations, and is characterized by an unstable 
tear film with decreased aqueous tear production.  Symptoms include irritation to the eye, such 
as burning, dryness, itching, scratching, and stinging (Merck Manual, 2003).  Even though KCS 
is the most common eye disease, affecting 4% of the general canine population (Williams et al., 
2008), it is under-diagnosed and poorly understood.  KCS in canines is most commonly caused 
by immune-mediated inflammation in the lacrimal glands, which results in decreased aqueous 
tear production.  Similar to that in canines, dry eye syndrome in humans can arise from 
numerous etiologies and affects over 25 million Americans (Seifert et al., 2012).  Sjögren’s 
Syndrome, a form of dry eye, is similar to canine KCS, as it has a strong autoimmune component 
and results in the destruction of the lacrimal and salivary gland tissues (Coursey et al., 2014).  As 
dry eye disease is often immune-mediated, both humans and canines typically require therapy 
throughout their lives.  
 As KCS must be addressed with a tear replacement therapy until the patient’s 
endogenous tear production has improved to a level adequate to alleviate symptoms, tear 
supplementation requires a frequent, lifelong treatment.  Therefore, to treat patients 
appropriately, it is necessary to determine the underlying cause of the KCS.  Currently, dogs 
diagnosed with immune-mediated KCS receive the topical immunosuppressive medication 
Cyclosporine A (Optimmune® 0.2% Ophthalmic Ointment) to increase aqueous tear production.  
Though many canines respond to therapy, they are dependent on this treatment with tear 
supplements for the remainder of their lives, and may experience persistent ocular discomfort, 
corneal opacification leading to vision loss, recurrent corneal ulceration and other complications.  
In human patients, the long-term therapies for dry eye include tear replacement and topical 
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cyclosporine A (Restasis® 0.05% Ophthalmic Suspension) (Kymionis et al., 2008).  Though this 
treatment results in increased tear production, patients have experienced minor adverse effects, 
such as a burning sensation at the time of topical application (Sall et al., 2000).  Therefore, the 
substantial subset of both canine and human patients that fail to respond to cyclosporine A 
treatment necessitates further research to identify a novel tear stimulating treatment.  
 Lacritin, a naturally occurring human tear glycoprotein approximately 12.3kDa in length 
(Ma et al., 2008), was discovered and characterized as a novel secretion enhancing factor from 
the human lacrimal gland (Sanghi et al., 2001).  This prosecretory mitogen consists of 119 amino 
acids and is found in the tear film of various species, including human, non-human primate, 
horse, dog and rodent (Laurie et al., 2012).  Characterized as a lacrimostimulant, topically 
applied Lacritin to rat and monkey lacrimal acinar cells in culture results in stimulated tear 
secretion (Sanghi et al., 2001).  Additionally, Lacritin is the only prosecretory protein 
downregulated in patients suffering from dry eye (Srinivasan et al., 2012), including those with 
Sjögren’s Syndrome and dryness related to contact lens wear (Aluru et al., 2012).  Synthesized in 
both human (Samudre et al., 2011) and canine (McKown et al., 2015) forms, recombinant 
Lacritin was topically applied to the eyes of normal rabbits three times daily for two weeks and 
demonstrated increased basal tear secretion throughout the two weeks and one week after 
treatment was ended (Samudre et al., 2011).  Thus, Lacritin’s potential to stimulate lacrimal 
tissue to secrete tears, combined with the finding of decreased tear Lacritin concentrations under 
dry eye conditions, promotes the investigation of Lacritin as a novel therapy for dry eye diseases.  
 Researchers from James Madison University (JMU), Walter Reed Army Medical Center 
(WRAMC), Eastern Virginia Medical School (EVMS), UVA, and other institutions established a 
consortium to study Lacritin as a potential therapeutic for the treatment of dry eye.  Through the 
4-VA Collaboration at JMU, a partnership was initiated with the Virginia-Maryland Regional 
College of Veterinary Medicine (VMCVM), where canine tear samples were collected.  A canine 
Lacritin ortholog gene was cloned, sequenced, and a recombinant canine Lacritin protein was 
expressed in E. coli and purified at JMU.  Canine Lacritin polyclonal antibodies were created 
and a canine Enzyme-Linked Immunosorbent Assay (ELISA) was developed to determine the 
concentration of Lacritin in tear samples. Thus, this study aimed to investigate if Lacritin is a 
biomarker of canine dry-eye disease and therefore is a candidate for a future canine KCS 
replacement therapy. 
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Summary of Previous Work 
N-terminal Antiserum Specificity Accomplished by Alan C. Tate, Honors Thesis, 2014 
Both normal and KCS canine tear samples were collected at the Virginia-Maryland 
Regional College of Veterinary Medicine.  Two -Lacritin human polyclonal rabbit antibodies 
were used to detect Lacritin in canine tears: an N-terminal antibody corresponding to the first 19 
amino acids of the human Lacritin N-terminus and the C-terminal antibody corresponding to a 
recombinant truncation mutant without the first 65 amino acids of the human Lacritin N-
terminus.  Tear wicks were eluted and assayed to find total tear protein concentrations.  An 
indirect ELISA and Western blot (Figure 1) were performed to analyze Lacritin concentrations.  
The ELISA standard curve was generated using recombinant human Lacritin (pLAC).  The C-
terminal antibody did not detect Lacritin, while the N-terminal antibody did. 
 
  
Figure 1. ELISA and western blot results.  (A) Lacritin concentrations in canine tear samples quantified with 
ELISA.  (B) Selected tear samples were separated by SDS PAGE and visualized with western blotting. Hu is human 
tears, OD is right eye and OS is left eye (Tate, Honors Thesis 2012).  
 
To improve the antibody sensitivity to Lacritin, the canine Lacritin gene was sequenced 
(Figure 2), cloned into the bacterial expression vector pTYB2, and purified through chitin 
affinity column and DEAE chromatography (Figure 2).  The amino acid sequence was 
determined and used to produce the N-terminal and C-terminal antiserums (Figure 2). 
A B 
ELISA Western Blot 
Blot 
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Figure 2. Purified recombinant canine Lacritin DNA gel, purified recombinant canine Lacritin SDS gel, and 
purified recombinant canine Lacritin amino acid sequence (Tate, Honors Thesis 2012). (A) Lane 1: 100 bp DNA 
ladder. Lane 2: amplified PCR product.  (B) Lane 1: molecular weight marker. Lane 2: cleared cell lysate prior to 
chitin affinity chromatography. Lane 3: fraction extracted after chitin affinity chromatography. Lane 4: DEAE 
Sepharose column, canine Lacritin 140 mM NaCl PBS elution.  (C) Amino acid sequence of recombinant canine 
Lacritin. N-terminal antibody (lightly shaded region) and C-terminal truncated antibody (darker shaded region). 
 
ELISA Development Accomplished by Alison M. Enghauser, Honors Thesis, 2015 
Canine Lacritin N-terminal antibodies were synthesized with above 90% purity and 
conjugated to keyhole limpet hemocyanin/bovine serum albumin (KLH/BSA) by Bio-Synthesis, 
Inc. (Lewisville, TX).  Two New Zealand white rabbits (6924 and 6925) were immunized with 
canine Lacritin and bled over a 10-week period to collect serum (Appendix C).  IgG antibodies 
from the -cLACRT NT antiserum were purified with Protein A coupled with agarose beads 
(Bio-Rad Laboratories, Hercules, CA).  An indirect ELISA was developed and titrated with the 
antibodies.  
Both normal and KCS canine tear samples were collected at the Virginia-Maryland 
Regional College of Veterinary Medicine.  Tear wicks were eluted and assayed to determine 
total tear protein.  An indirect ELISA and Western blot (Figure 3,4) were performed to analyze 
Lacritin concentrations in tear samples using the 10 week -cLACRT NT PA purified antiserum 
(6924 FB PANT) and a secondary antibody (HRP-conjugated goat -rabbit IgG).  
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Figure 3. Indirect ELISA of Lacritin in canine tears. Summary of canine tear Lacritin in normal (blue) and dry 
eye (red) tear samples as determined by indirect ELISA (Enghauser, Honors Thesis 2014). 
 
Figure 4. Western blot analysis of normal and dry-eye canine tears. Dry eye tear samples 66, 59, and 44 
(OD/OS) and normal tear sample A1 (OD/OS). The band corresponding to monomeric canine Lacritin is seen at ~18 
kDa. Higher molecular weights are cross-linked variations of Lacritin. (Enghauser et. al., 2014) 
 
 
 
   10 
Clinical Study Accomplished by Katherine E. Kelly, Honors Thesis 2016 
Tear samples were collected from canines being treated at Virginia-Maryland College of 
Veterinarian Medicine and transported to JMU for analysis. At JMU, the tears were eluted from 
the wicks and assayed to determine total protein concentrations. An indirect ELISA was 
developed and optimized to quantitate total tear Lacritin. SDS-PAGE was used to visualize the 
tear total protein profile.  Western blot analysis was used to visually determine monomeric and 
higher order complexes of canine Lacritin in tear samples.  A total of 64 tear samples were 
analyzed with 32 samples from healthy dogs and 32 samples from dogs clinically diagnosed with 
dry eye. Canines with KCS had a significant decrease in tear film Lacritin as determined by 
ELISA analysis.  Western blot analysis detected prominent bands in healthy tears at 
approximately 18 kDa corresponding to monomeric canine Lacritin that were absent or reduced 
in tears from dry eye dogs.  This study provides clinical data that supports the application of 
Lacritin as a topical therapeutic for the treatment of dry eye disease (Figure 5). 
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Figure 5. Western blot analysis of dry-eye and normal samples. Western Blot analysis of the samples with their 
STT values and Lacritin concentrations as determined by the indirect ELISA listed below. An STT value below 15 
indicates dry eye, while above indicates normal tearing levels. The band corresponding to monomeric canine 
Lacritin is seen at ~18 kDa. Higher molecular weights are cross-linked variations of Lacritin. N = Dry eye tear 
samples and N = Normal tear samples.  Lacritin values are ng per 50 ng total tear protein as determined by the 
ELISA.   
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 This study aimed to analyze the amount of Lacritin present in both normal and dry-eye 
canine tear samples. Prior to sample arrival to JMU, canine Lacritin polyclonal antibodies were 
titrated to maximize detection for assays, and the canine indirect ELISA was optimized to 
reliably determine the concentration of Lacritin in tear samples.  
 
MATERIALS AND METHODS 
Collection and Elution of Tears 
Both normal and KCS canine tear samples were collected at the Virginia-Maryland 
Regional College of Veterinary Medicine at Virginia Tech by Julie Disney, DVM.  Canines were 
either previously diagnosed with dry-eye or had a Shirmer Tear Test (STT) performed to 
determine the rate (mm/min) of tear production and generate an STT value. An STT value of 
15mm/min or higher was classified as normal, while an STT value of 14mm/min or lower was 
classified as dry-eye. Wicks were applied to the canine’s ocular surface for approximately 1 
minute and stored in microcentrifuge tubes at -20°C. A total of 46 samples were collected, 24 
normal and 22 diagnosed with KCS. Of the 24 normal canines, only one was on treatment; of the 
22 KCS canines, eleven were on treatment. Samples were divided into 6 sets (I-VI) and labeled 
with the canine identification number and oculus dexter (OD) for right eye or oculus sinister 
(OS) for left eye.  Tears were eluted from the wicks with 30μL of filter-sterilized 1X phosphate 
buffered saline (FSPBS) and incubated for 20 minutes at 37°C.  Eluted tears were spun at 13,000 
rpm for 5 minutes, total volume was recorded, and samples were then stored at -20°C for future 
analysis. 
 
Bicinchoninic Acid Assay 
The Thermo Scientific Pierce BCA Protein Assay Kit was used to determine the total tear 
protein concentration in the samples compared to a protein standard.  BCA samples were 
prepared in microcentrifuge tubes by combining 4 μL of the eluted sample with 20 μL FSPBS.  
Duplicate standards and samples were plated in a 96 well microtiter plate, incubated at 37°C for 
30 minutes, and then measured at 570 nm in a spectrometer.  Standard protein concentrations 
versus absorbance values were graphed to generate a linear trend line and the coefficient of 
determination.  The total tear protein concentration of each sample was calculated.  
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Antibody Specificity and Titration 
To determine the optimal dilutions of both primary and secondary antibodies for the 
ELISA standard curve, 10-week Final Bleed N-Terminal Protein A purified primary antibodies 
(6924 FB PANT) from rabbit 6924 were titrated against recombinant canine Lacritin. In a 96 
well microtiter plate, previously cloned and purified lyophilized recombinant canine Lacritin 
(cLAC) was diluted with coating buffer from 0.1 to 1000 ng/mL. In the same microtiter plate, 
6924 PANT FB antibodies were diluted with a 1X PBS and 0.3% Tween20 solution (PBST) 
from 1:200 to 1:12800. The secondary antibody, HRP-conjugated goat -rabbit IgG, was diluted 
in PBST to 1:400 and applied to the wells. The absorbance values were plotted and analyzed; the 
dilution that produced the most linear standard curve was chosen as the optimal dilution used for 
the ELISA. 
 
Indirect Enzyme-Linked Immunosorbent Assay 
The indirect ELISA was used to determine the total Lacritin concentration in the samples 
compared to a Lacritin standard.  To generate a standard curve for comparison, cLAC was 
resuspended with 100μL of deionized water (dH2O) and diluted to 32ng/mL with coating buffer 
(4.53mL 1.0M NaHCO3, 1.82mL 1.0M Na2CO3, 93.65mL dH2O).  The standard 32ng/mL stock 
was diluted and plated (100μL) in triplicate in a 96 well microtiter plate at 32, 24, 16, 12, 8, 6, 4, 
3, 2, 1.5, 1, 0.5, and 0 ng concentrations.  Plates were duplicated and incubated at 4°C for 24 
hours. 
Wells were washed three times with 300μL of PBST, and excess liquid was expelled.  
Plates were coated with 300μL of 1% w/v blocking buffer (0.2g BSA, 20mL PBS) and incubated 
for 35min at 37°C.  Wells were washed three times with 300μL PBST, and excess liquid was 
expelled.  Primary antibody (6924 FB PANT) was diluted at 1:3200 in PBST and then 100μL 
was pipetted into each well.  Plates were incubated for 35min at 37°C.  Wells were washed three 
times with 300μL PBST, and excess liquid was expelled.  Secondary antibody (HRP-conjugated 
goat -rabbit IgG) was diluted at 1:400 in PBST and then 100μL was pipetted into each well.  
Plates were incubated for 35min at 37°C.  Wells were washed three times with 300μL PBST, and 
excess liquid was expelled.  Substrate (6.0mL 0.1M C6H8O7, 6.5mL 0.2M Na2HPO4, 12.5mL 
dH2O, 10μL H2O2, 10mg o-phenylenediamine dihydrochloride) was prepared using a vortex and 
100μL was pipetted into each well.  Plates were incubated at room temperature in the dark for 
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10min and then measured at 415nm in a spectrometer.  Standard Lacritin concentrations versus 
absorbance values were graphed to generate a linear trend line and the coefficient of 
determination.  The total Lacritin protein concentration of each sample was calculated. 
 
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis & Western Blots 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and western 
blotting with cLAC antibodies were used to analyze the abundance of monomeric Lacritin in tear 
samples. Samples were normalized with PBS and 4μL of 6x loading dye was added to each 
sample. Samples were boiled for 5 minutes, and 10μL of each sample and 7μL of protein ladder 
(Precision Plus Protein Kaleidoscope Standards, BioRad) were loaded into the gel (Any kD 
Mini-PROTEAN TGX Precast Gel). Tris-glycine buffer (BioRad) was added, and the gel 
was run at 200 volts; the gel was stopped when the loading dye front reached the bottom.  
The samples were transferred onto nitrocellulose membrane with a trans-blot apparatus 
(Appendix C). The blot was run at 100 volts for one hour. Membranes were removed and stored 
at 4°C overnight in aluminum foil. The membranes were washed for ten minutes with PBST four 
times, and primary antibody at a 1:1000 dilution in PBST was added for one hour at room 
temperature. During this incubation, the membranes were agitated constantly by a shaker. The 
membranes were washed for ten minutes with PBST four times, and secondary antibody at a 
1:5000 dilution in PBST was added for one hour at room temperature. During this incubation, 
the membranes were agitated constantly by a shaker. The membranes were washed twice for 
fifteen minutes with PBST, and then wicked and stored.  
Membranes were taken to a dark room and film was developed via the chemiluminescent 
reaction between the horseradish peroxidase and ECL substrate (Pierce ECL Western Blotting 
Substrate, Thermo Fisher Scientific Inc.). Membranes were submersed in substrate for one 
minute and wrapped in Saran wrap. The membranes were placed face down on a sheet of x-ray 
film for an appropriate exposure time (10-25 seconds). Films were bathed in successive baths of 
developing solutions (developer, deionized water, fixer, and deionized water) for 30-second 
intervals.  Solution baths were constantly agitated.  
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Densitometry  
Densitometry was used to determine the amount of the active Lacritin monomer (~18 
kDa) band present. Previously exposed x-ray films were imaged using the gel documentation 
system (Image Lab software, Bio-Rad), and the relative signal intensity of the Lacritin monomer 
band was quantified.  
 
Statistical Analysis  
An unpaired t-test was performed using the mean, standard deviation and the number of 
samples to compare dry-eye and normal data and determine a level of significance. A p-value 
less than or equal to 0.05 between samples was considered a significant difference as it was 
unlikely to be a chance event.  
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RESULTS 
 
Bicinchoninic Acid Assay 
 The total tear protein concentration of the untreated dry eye samples (Table 1) had a 
range of 824.9 to 2510.2µg/mL, an average of 1664.5µg/mL and a median of 1688.8 µg/mL. 
Two untreated dry-eye samples had total tear protein concentrations further than three standard 
deviations from the average, and thus were excluded from the data (SD = 597.6 µg/mL). The 
total tear protein concentration of the treated dry eye samples (Table 2) had a range of 928.2 to 
2106.9µg/mL, while the average was 1439.9µg/mL and the median was 1335.8µg/mL. The total 
tear protein concentration of the untreated normal samples (Table 3) had a range of 615.8 to 
1758.6µg/mL, while the average was 1235.1µg/mL and the median was 1207.1µg/mL. The total 
tear protein concentration of the treated normal sample (Table 4) was 1542.2µg/mL.  All assays 
had a standard curve with a coefficient of determination (R2) value above 0.99 (Figure 6), and 
the raw data is shown in Appendix A.  
Figure 6. BCA analysis of canine tears. BCA assay standard curve for Set I of the canine tear samples.   
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Table 1. Dry-eye total tear protein concentrations for untreated dry-eye canines. Sample identifier (OD = right, 
OS= left), STT value, and total tear protein concentrations in untreated dry-eye canines. 
Sample STT Value 
Total Protein 
(ug/mL) 
OD 140939 11 1421.6 
OD 139969 8 2197.7 
OS 139969 11 824.9 
OD 139857 11 959.3 
OS 139857 8 1192.1 
OD 105139 9 2145.7 
OD 140221 10 2040.3 
OS 140221 10 1688.8 
OD 112296 9  -- 
OS 112296 16  -- 
OS 140688 6 2510.2 
 
Table 2. Dry-eye total tear protein concentrations for treated dry-eye canines. Sample identifier (OD = right, 
OS= left), STT value, and total tear protein concentrations in treated dry-eye canines. 
Sample STT Value 
Total Protein 
(ug/mL) 
OD 92754 17 1256.1 
OS 92754 18 1029.4 
OS 140932 22 1932.2 
OD 133815 16 951.0 
OS 136979 30 1325.6 
OS 140818 25 2106.9 
OD 102140 25 1517.9 
OS 102140 7 1335.8 
OD 132730 20 928.2 
OS 132730 19 1430.2 
OD 140932 21 2025.7 
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Table 3. Normal total tear protein concentrations for untreated normal canines. Sample identifier (OD = right, 
OS= left), STT value, and total tear protein concentrations in untreated normal canines. 
Sample STT Value 
Total Protein 
(ug/mL) 
OD 131440 19 1758.6 
OS 131440 18 1207.1 
OD 138958 22 833.3 
OS 138958 25 1182.6 
OS 140939 22 1850.5 
OD 123271 16 1028.2 
OS 123271 20 768.4 
OD 141005 25 615.8 
OS 141005 25 853.1 
OD 141938 24 1106.9 
OS 141938 23 1538.3 
OD 141947 23 1141.0 
OS 141947 25 777.7 
OS 105139 20 1021.8 
OD 141920 25 1389.0 
OS 141920 23 1360.2 
OD 138399 20 1371.8 
OS 138399 25 1285.3 
OD 130089 15 1633.3 
OS 130089 14 1621.1 
OD 128357 15 1605.4 
OS 128357 19 1389.4 
OD 140688 19 1068.3 
 
Table 4. Normal total tear protein concentrations for treated normal canines. Sample identifier (OD = right, 
OS= left), STT value, and total tear protein concentrations in normal canines. 
Sample STT Value 
Total Protein 
(ug/mL) 
OD 140818 24 1542.2 
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Antibody Specificity and Titration 
 Lacritin signal was detected at concentrations greater than 0.1 ng/mL (Figure 7) by 6924 
PANT FB. The titration determined that 6924 PANT FB diluted in PBST to 1:3200 and 
secondary antibody diluted in PBST to 1:400 produced the most linear standard curve, and was 
used for the ELISAs.  
 
 
Figure 7. Titration of 6924 FB PANT antibodies. Final bleed N-Terminal protein A purified primary antibodies 
(6924 FB PANT) from rabbit 6924 were titrated against recombinant canine Lacritin (cLAC). cLAC was diluted 
from 0.1 to 1000 ng/mL and primary antibody was diluted from 1:200 to 1:12800.  
 
Indirect Enzyme-Linked Immunosorbent Assay 
 Lacritin concentrations were quantified using a 32ng Lacritin per 50ng total tear protein 
standard curve. Each plate was done in duplicate, and each sample was assayed in triplicate. Any 
samples with a concentration higher than 32ng Lacritin per 50ng total tear protein were not 
included to prevent extrapolation error. The Lacritin concentration of the untreated dry-eye 
samples (Table 5) had a range of 7.7 to 29.0ng Lacritin per 50ng total tear protein, while the 
average was 18.0ng Lacritin per 50ng total tear protein and the median was 22.1ng Lacritin per 
50ng total tear protein. The Lacritin concentration of the treated dry-eye samples (Table 6) had a 
range of 17.3 to 23.8ng Lacritin per 50ng total tear protein, while the average was 19.2ng 
Lacritin per 50ng total tear protein and the median was 18.2ng Lacritin per 50ng total tear 
protein.  Two samples had Lacritin concentrations that exceeded the assay’s maximum boundary 
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of 32ng per 50ng total tear protein, and thus, were excluded from the data to prevent 
extrapolation errors (Table 6). The Lacritin concentration of the untreated normal samples (Table 
7) had a range of 15.1 to 28.8ng Lacritin per 50ng total tear protein, while the average was 
22.0ng Lacritin per 50ng total tear protein and the median was 22.3ng Lacritin per 50ng total tear 
protein. The Lacritin concentration of the treated normal sample (Table 8) was 23.5ng Lacritin 
per 50ng total tear protein. All assays had a standard curve with an R2 value above 0.98 (Figure 
8), and the raw data is shown in Appendix B.  
 
Figure 8.  Indirect ELISA Standard Curve. The total tear Lacritin concentrations plotted as a standard curve with 
a coefficient of determination above 0.99.  
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Table 5. Dry-eye total Lacritin concentrations for untreated dry-eye canines. Sample identifier (OD = right, 
OS= left), STT value, and total Lacritin concentrations in untreated dry-eye canines. 
Sample STT Value 
Lacritin (ng/50 ng total 
protein) 
OD 140939 11 29.0 
OD 139969 8 10.1 
OS 139969 11 22.5 
OD 139857 11 22.1 
OS 139857 8 26.1 
OD 105139 9 7.8 
OD 140221 10 24.9 
OS 140221 10 28.1 
OD 112296 9 7.7 
OS 112296 16 8.3 
OS 140688 6 11.3 
 
 
Table 6. Dry-eye total Lacritin concentrations for treated dry-eye canines. Sample identifier (OD = right, OS= 
left), STT value, and total Lacritin concentrations in treated dry-eye canines. 
Sample STT Value Lacritin (ng/50 ng total protein) 
OD 92754 17 20.6 
OS 92754 18 23.8 
OS 140932 22 17.3 
OD 133815 16 -- 
OS 136979 30 -- 
OS 140818 25 20.2 
OD 102140 25 17.7 
OS 102140 7 17.3 
OD 132730 20 18.2 
OS 132730 19 20.0 
OD 140932 21 17.4 
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Table 7. Normal total Lacritin concentrations for untreated normal canines. Sample identifier (OD = right, 
OS= left), STT value, and total Lacritin concentrations in untreated normal canines. 
Sample STT Value 
Lacritin (ng/50 ng total 
protein) 
OD 131440 19 23.8 
OS 131440 18 22.5 
OD 138958 22 18.1 
OS 138958 25 22.6 
OS 140939 22 27.7 
OD 123271 16 25.5 
OS 123271 20 23.5 
OD 141005 25 22.5 
OS 141005 25 18.9 
OD 141938 24 21.6 
OS 141938 23 18.9 
OD 141947 23 20.4 
OS 141947 25 18.3 
OS 105139 20 22.3 
OD 141920 25 28.8 
OS 141920 23 25.3 
OD 138399 20 23.5 
OS 138399 25 25.5 
OD 130089 15 19.9 
OS 130089 14 15.1 
OD 128357 15 19.8 
OS 128357 19 19.9 
OD 140688 19 21.4 
 
Table 8. Normal total Lacritin concentrations for treated normal canines. Sample identifier (OD = right, OS= 
left), STT value, and total Lacritin concentrations in treated normal canines.  
Sample STT Value 
Lacritin (ng/50 ng total 
protein) 
OD 140818 24 24.0 
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Western Blots and Densitometry  
 The monomeric Lacritin band (~18kDa) was visualized via western blotting (Figure 9). 
The boldness of the band indicated how much Lacritin was detected; thus, thicker bands 
represented samples with more Lacritin present. Additionally, banding was present above the 
20kDa marker. This indicated crosslinking of higher weight molecules occurred, which caused 
the formation of protein complexes. One sample in Set II was excluded, as the same sample was 
repeated later in Set VI. The Lacritin concentration of two samples from Set IV were excluded, 
as determining their values would have required extrapolation from the standard curve.   
   24 
  
Figure 9. Visualization of monomeric Lacritin in canine samples. Western blot analysis of the samples. Tear 
status, STT value, and Lacritin concentrations (ng/50ng) determined with the ELISA are depicted within each lane. 
The band corresponding to monomeric canine Lacritin is seen at ~18 kDa. Higher molecular weights are cross-
linked variations of Lacritin. DE = Dry eye tear samples, N = Normal tear samples, E = Excluded tear sample due to 
extrapolation.  Lacritin values are ng per 50 ng total tear protein as determined by the ELISA. 
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Densitometry of the western blot determined that the relative intensity of the untreated 
dry-eye samples (Table 9) had a range of 2.50x106 to 2.40x108, while the average was 6.43x107 
and the median was 2.68x107. The relative intensity of the treated dry-eye samples (Table 10) 
had a range of 4.04x107 to 2.42x108, while the average was 1.01x108 and the median was 
5.65x107. The relative intensity of the untreated normal samples (Table 11) had a range of 
3.43x107 to 2.40x108, while the average was 1.25x108 and the median was 1.18x107. The relative 
intensity of the treated normal sample (Table 12) was 2.30x108. 
Table 9. Relative intensity of Lacritin monomer band in untreated dry-eye canines. Sample identifier (OD = 
right, OS= left), STT value, and densitometry to determine the relative intensity of the canine Lacritin monomer 
band in untreated dry-eye samples.  
Sample STT Value 
Relative 
Intensity (*106) 
OD 140939 11 115.6 
OD 139969 8 13.8 
OS 139969 11 86.5 
OD 139857 11 130.4 
OS 139857 8 240.6 
OD 105139 9 4.50 
OD 140221 10 66.6 
OS 140221 10 26.8 
OD 112296 9 3.91 
OS 112296 16 2.50 
OS 140688 6 15.8 
 
Table 10. Relative intensity of Lacritin monomer band in treated dry-eye canines. Sample identifier (OD = 
right, OS= left), STT value, and densitometry to determine the relative intensity of the canine Lacritin monomer 
band in treated dry-eye samples. 
Sample STT Value 
Relative Intensity 
(*106) 
OD 92754 17 40.4 
OS 92754 18 48.7 
OS 140932 22 56.5 
OD 133815 16 60.8 
OS 136979 30 43.2 
OS 140818 25 238.1 
OD 102140 25 195.0 
OS 102140 7 45.5 
OD 132730 20 242.3 
OS 132730 19 89.6 
OD 140932 21 49.6 
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Table 11. Relative intensity of Lacritin monomer band in untreated normal canines. Sample identifier (OD = 
right, OS= left), STT value, and densitometry to determine the relative intensity of the canine Lacritin monomer 
band in untreated normal samples. 
Sample STT Value 
Relative 
Intensity (*106) 
OD 131440 19 90.5 
OS 131440 18 70.1 
OD 138958 22 40.1 
OS 138958 25 121.5 
OS 140939 22 129.2 
OD 123271 16 189.1 
OS 123271 20 200.3 
OD 141005 25 224.0 
OS 141005 25 239.8 
OD 141938 24 151.2 
OS 141938 23 91.8 
OD 141947 23 82.1 
OS 141947 25 108.0 
OS 105139 20 139.3 
OD 141920 25 34.3 
OS 141920 23 70.7 
OD 138399 20 118.1 
OS 138399 25 64.1 
OD 130089 15 78.6 
OS 130089 14 169.5 
OD 128357 15 226.1 
OS 128357 19 183.4 
OD 140688 19 47.7 
 
Table 12. Relative intensity of Lacritin monomer band in treated normal canines. Sample identifier (OD = 
right, OS= left), STT value, and densitometry to determine the relative intensity of the canine Lacritin monomer 
band in treated, normal samples. 
Sample STT Value 
Relative 
Intensity (*106) 
OD 140818 24 230.1 
 
STT Comparison 
 Schirmer Tear Test (STT) values were plotted against the total tear protein concentration, 
total Lacritin concentration, and relative intensity of the untreated samples (Figure 10, 12, 14) 
and of the treated samples (Figure 11, 13, 15). The STT is used to measure tearing rates in 
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humans and canines as a means to diagnose dry-eye syndrome. In canines, 15mm/min or above 
indicates normal tear production, whereas anything below that rate indicates dry-eye.  
 
Figure 10. STT values versus total tear protein for untreated canines. A scatterplot of STT values against total 
tear protein in untreated dry-eye and normal canines.  
 
 
Figure 11. STT values versus total tear protein for treated canines. A scatterplot of STT values against total tear 
protein in treated dry-eye and normal canines.  
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Figure 12. STT values versus Lacritin concentration for untreated canines. A scatterplot of STT values against 
Lacritin concentration in untreated dry-eye and normal canines.  
 
 
Figure 13. STT values versus Lacritin concentration for treated canines. A scatterplot of STT values against 
Lacritin concentration in treated dry-eye and normal canines.  
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Figure 14. STT values versus relative intensity for untreated canines. A scatterplot of STT values against 
relative intensity of the Lacritin monomer band (~18kDa) visualized with a western blot for untreated dry-eye and 
normal canines.  
 
 
Figure 15. STT values versus relative intensity for treated canines. A scatterplot of STT values against relative 
intensity of the Lacritin monomer band (~18kDa) visualized with a western blot for treated dry-eye and normal 
canines.  
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DISCUSSION 
 In previous research, the canine Lacritin gene was sequenced, cloned, and purified. The 
amino acid sequence was used to produce canine N-terminal antiserum, which were titrated for 
use in an indirect ELISA. Western blot analysis revealed monomeric Lacritin banding was 
present in normal canine samples, but faint or absent in dry-eye canine samples. 
In this canine clinical study, 46 tear samples – 24 samples from normal canines and 22 
samples from canines diagnosed with KCS – were collected by Julie Disney, DVM, through a 
collaboration with the Virginia-Maryland College of Veterinarian Medicine. Samples were 
transported to James Madison University (JMU) for analysis, where total tear protein and 
Lacritin concentration was determined. Monomeric Lacritin was visualized and the relative 
intensity was quantified with western blotting and densitometry.  
 Prior to or at the time of collection, canines were designated a tear status of normal or 
dry-eye. Traditionally, patients are diagnosed with dry-eye using the Shirmer Tear Test (STT) 
and assigned an STT value, which measures tear production in mm/min. Canines with an STT 
value less than 15mm/min are diagnosed with dry-eye, while canines with an STT value greater 
or equal to 15mm/min are classified as normal. As determined by this study, many canines 
classified as dry-eye had STT values of 15mm/min or higher, signifying normal tear production 
despite the diagnosis. However, this increase in STT value may have been observed due to 
several variables. Several of the patients were diagnosed previous to collection and had been on 
treatment for several months or years. Therefore, treatment may have inflated STT values in 
canines with dry-eye tear statuses. To examine the relationship between treatment and STT value 
in future studies, data should be collected solely from untreated canines.  
 As determined with BCA analysis, the total tear protein concentration in untreated dry-
eye canines was significantly greater than the total tear protein concentration in untreated normal 
canines (p-value: 0.0152), with a mean of ~1665g/mL for dry-eye and ~1235g/mL for normal 
samples. This increase may have been the result of several variables. Canines diagnosed with 
dry-eye often have irritation and inflammation in their eyes due to dryness or other dry-eye 
related symptoms. Thus, there are potentially higher amounts of immune response proteins 
located in and around their tear ducts. Additionally, as there is less tearing at the ocular surface, 
the concentration in the tear samples may have been higher due to less liquid present at 
collection. 
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 The Lacritin concentration in untreated dry-eye canines was not significantly different to 
the Lacritin concentration in untreated normal canines (p-value: 0.0626). The mean Lacritin 
concentration in untreated dry-eye canines was ~18ng/50ng total protein, while the mean Lacritin 
concentration in untreated normal canines was ~22ng/50ng total protein. As the p-value was 
0.0126 away from indicating a significant difference between Lacritin concentrations in 
untreated dry-eye and normal canines, additional clinical data should be collected and analyzed.  
 Densitometry analysis revealed that the relative intensity of the monomeric Lacritin band 
in untreated dry-eye canines was significantly lower than the relative intensity of the monomeric 
Lacritin band in untreated normal canines (p-value: 0.0190), with a mean of 6.43x107 for dry-eye 
and 1.25x108 for normal. Therefore, this indicated that normal canines had more abundant 
monomeric Lacritin bands than dry-eye canines. While this data indicates a significant 
difference, while the ELISA data does not, additional clinical data should be collected and 
analyzed. Additionally, Lacritin complexes were detected higher than 18kDA, indicating cross-
linked Lacritin. Tissue transglutaminase is known to cross-link Lacritin and causes the formation 
of higher molecular weight complexes, visualized with western blotting; this form of Lacritin is 
shown to be inactive (Velez, 2013).  
 Overall, a canine Lacritin detection and quantification system was developed to analyze 
the total protein, the total Lacritin concentration, and the relative intensity of monomeric Lacritin 
in clinical canine samples. Dry-eye samples had a significantly higher total protein concentration 
than normal samples, but a significantly lower relative intensity of the monomeric Lacritin band 
than normal samples. There was no significant difference in total Lacritin concentration between 
dry-eye and normal canines, as determined by the ELISA. Thus, the lower relative intensity of 
monomeric Lacritin present in canines with dry-eye suggests that monomeric Lacritin has 
potential as a biomarker of KCS, and should researched further to determine if Lacritin holds 
promise as a potential therapeutic for dry-eye syndrome.   
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APPENDIX A 
BCA Canine Samples 11-29-16 SET I 
          
  
ABS 
1 
ABS 
2 AVG ST. DEV. Conc (mg/mL) Corrected 
  
  
1.048 1.021 1.035 0.019 2.000 0.961 
  
  
0.845 0.780 0.813 0.046 1.500 0.739 
  
  
0.574 0.563 0.569 0.008 1.000 0.495 
  
  
0.439 0.469 0.454 0.021 0.750 0.381 
  
  
0.302 0.356 0.329 0.038 0.500 0.256 
  
  
0.226 0.236 0.231 0.007 0.250 0.158 
  
  
0.117 0.150 0.134 0.023 0.125 0.060 
  
  
0.080 0.083 0.082 0.002 0.025 0.008 
  
  
0.073 0.074 0.074 0.001 0.000 0.000 
  
  
 
        
          
          
          
          
          
          
          
          
          
          
          
        
 
 
          
          
 
Sample 
ABS 
1 
ABS 
2 AVG ST DEV corrected mg/mL ug/mL 6x 
 
OD 131440 0.220 0.214 0.217 0.004 0.144 0.29310 293.0964052 1758.578431 
 
OS 131440 0.183 0.161 0.172 0.016 0.099 0.20118 201.1846405 1207.107843 
 
OD 138958 0.145 0.138 0.142 0.005 0.068 0.13889 138.8888889 833.3333333 
 
OS 138958 0.168 0.172 0.170 0.003 0.097 0.19710 197.0996732 1182.598039 
 
OD 92754 0.178 0.174 0.176 0.003 0.103 0.20935 209.3545752 1256.127451 
 
OS 92754 0.158 0.157 0.158 0.001 0.084 0.17157 171.5686275 1029.411765 
 
OD 140939 0.181 0.198 0.190 0.012 0.116 0.23693 236.9281046 1421.568627 
 
OS 140939 0.230 0.219 0.225 0.008 0.151 0.30842 308.4150327 1850.490196 
 
 
 
y = 0.4896x
R² = 0.9979
0.0
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0.4
0.6
0.8
1.0
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0.0 0.5 1.0 1.5 2.0
A
b
s
Protein Conc mg/mL
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BCA Canine Samples 11-29-16 SET II 
          
  
ABS 
1 
ABS 
2 AVG ST. DEV. Conc (mg/mL) Corrected 
  
  
1.147 1.081 1.114 0.047 2.000 1.040 
  
  
0.905 0.801 0.853 0.074 1.500 0.779 
  
  
0.622 0.621 0.622 0.001 1.000 0.547 
  
  
0.498 0.515 0.507 0.012 0.750 0.432 
  
  
0.395 0.376 0.386 0.013 0.500 0.311 
  
  
0.231 0.234 0.233 0.002 0.250 0.158 
  
  
0.156 0.157 0.157 0.001 0.125 0.082 
  
  
0.088 0.085 0.087 0.002 0.025 0.012 
  
  
0.074 0.075 0.075 0.001 0.000 0.000 
  
  
 
        
          
          
          
          
          
          
          
          
          
          
          
        
 
 
          
          
 
Sample 
ABS 
1 
ABS 
2 AVG ST DEV corrected mg/mL ug/mL 6x 
 
OD 123271 0.171 0.160 0.166 0.008 0.091 0.17137 171.3747646 1028.248588 
 
OS 123271 0.146 0.139 0.143 0.005 0.068 0.12806 128.0602637 768.3615819 
 
OD 141005 0.125 0.133 0.129 0.006 0.055 0.10264 102.6365348 615.819209 
 
OS 141005 0.149 0.151 0.150 0.001 0.076 0.14218 142.1845574 853.1073446 
 
OD 139969 0.262 0.276 0.269 0.010 0.195 0.36629 366.2900188 2197.740113 
 
OS 139969 0.143 0.152 0.148 0.006 0.073 0.13748 137.4764595 824.8587571 
 
OD 140932 0.415 0.279 0.347 0.096 0.273 0.51318 513.1826742 3079.096045 
 
OS 140932 0.240 0.251 0.246 0.008 0.171 0.32203 322.0338983 1932.20339 
 
 
 
 
y = 0.531x
R² = 0.9951
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0.0 0.5 1.0 1.5 2.0
A
b
s
Protein Conc mg/mL
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BCA Canine Samples 11-30-16 SET III 
          
  
ABS 
1 
ABS 
2 AVG ST. DEV. Conc (mg/mL) Corrected 
  
  
1.086 1.094 1.090 0.006 2.000 1.015 
  
  
0.856 0.853 0.855 0.002 1.500 0.779 
  
  
0.645 0.651 0.648 0.004 1.000 0.573 
  
  
0.505 0.521 0.513 0.011 0.750 0.438 
  
  
0.378 0.384 0.381 0.004 0.500 0.306 
  
  
0.238 0.241 0.240 0.002 0.250 0.164 
  
  
0.152 0.160 0.156 0.006 0.125 0.081 
  
  
0.092 0.091 0.092 0.001 0.025 0.016 
  
  
0.074 0.077 0.076 0.002 0.000 0.000 
  
  
 
        
          
          
          
          
          
          
          
          
          
          
          
        
 
 
          
          
 
Sample 
ABS 
1 
ABS 
2 AVG ST DEV corrected mg/mL ug/mL 6x 
 
OD 141938 0.180 0.166 0.173 0.010 0.098 0.18448 184.4843898 1106.906339 
 
OS 141938 0.217 0.205 0.211 0.008 0.136 0.25639 256.3859981 1538.315989 
 
OD 141947 0.172 0.180 0.176 0.006 0.101 0.19016 190.1608325 1140.964995 
 
OS 141947 0.145 0.143 0.144 0.001 0.069 0.12961 129.6121097 777.6726585 
 
OD 139857 0.157 0.163 0.160 0.004 0.085 0.15989 159.8864711 959.3188269 
 
OS 139857 0.176 0.185 0.181 0.006 0.105 0.19868 198.6754967 1192.05298 
 
OD 105139 0.263 0.266 0.265 0.002 0.189 0.35762 357.615894 2145.695364 
 
OS 105139 0.166 0.165 0.166 0.001 0.090 0.17029 170.2932829 1021.759697 
 
 
 
 
y = 0.5285x
R² = 0.9916
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0.0 0.5 1.0 1.5 2.0
A
b
s
Protein Conc mg/mL
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BCA Canine Samples 11-30-16 SET IV 
          
  
ABS 
1 
ABS 
2 AVG ST. DEV. Conc (mg/mL) Corrected 
  
  
1.101 1.059 1.080 0.030 2.000 1.007 
  
  
0.855 0.839 0.847 0.011 1.500 0.774 
  
  
0.631 0.610 0.621 0.015 1.000 0.548 
  
  
0.487 0.494 0.491 0.005 0.750 0.418 
  
  
0.375 0.377 0.376 0.001 0.500 0.303 
  
  
0.232 0.232 0.232 0.000 0.250 0.159 
  
  
0.156 0.159 0.158 0.002 0.125 0.085 
  
  
0.088 0.088 0.088 0.000 0.025 0.015 
  
  
0.073 0.073 0.073 0.000 0.000 0.000 
  
  
 
        
          
          
          
          
          
          
          
          
          
          
          
        
 
 
          
          
 
Sample 
ABS 
1 
ABS 
2 AVG ST DEV corrected mg/mL ug/mL 6x 
 
OD 141920 0.187 0.200 0.194 0.009 0.121 0.23151 231.5081652 1389.048991 
 
OS 141920 0.197 0.185 0.191 0.008 0.118 0.22671 226.7050913 1360.230548 
 
OD 138399 0.189 0.195 0.192 0.004 0.119 0.22863 228.6263208 1371.757925 
 
OS 138399 0.182 0.187 0.185 0.004 0.112 0.21422 214.2170989 1285.302594 
 
OD 140221 0.237 0.263 0.250 0.018 0.177 0.34006 340.0576369 2040.345821 
 
OS 140221 0.208 0.231 0.220 0.016 0.147 0.28146 281.4601345 1688.760807 
 
OD 133815 0.155 0.156 0.156 0.001 0.083 0.15850 158.5014409 951.0086455 
 
OS 136979 0.185 0.191 0.188 0.004 0.115 0.22094 220.9414025 1325.648415 
 
 
 
 
y = 0.5205x
R² = 0.9943
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0.0 0.5 1.0 1.5 2.0
A
b
s
Protein Conc mg/mL
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BCA Canine Samples 12-1-16 SET V 
          
  
ABS 
1 
ABS 
2 AVG ST. DEV. Conc (mg/mL) Corrected 
  
  
1.035 0.984 1.010 0.036 2.000 0.939 
  
  
0.852 0.802 0.827 0.035 1.500 0.756 
  
  
0.607 0.596 0.602 0.008 1.000 0.531 
  
  
0.463 0.470 0.467 0.005 0.750 0.396 
  
  
0.343 0.352 0.348 0.006 0.500 0.277 
  
  
0.210 0.229 0.220 0.013 0.250 0.149 
  
  
0.136 0.145 0.141 0.006 0.125 0.070 
  
  
0.081 0.088 0.085 0.005 0.025 0.014 
  
  
0.068 0.074 0.071 0.004 0.000 0.000 
  
  
 
        
          
          
          
          
          
          
          
          
          
          
          
        
 
 
          
          
 
Sample 
ABS 
1 
ABS 
2 AVG ST DEV corrected mg/mL ug/mL 6x 
 
OD 130089 0.207 0.204 0.206 0.002 0.135 0.27221 272.2121028 1633.272617 
 
OS 130089 0.206 0.203 0.205 0.002 0.134 0.27019 270.188221 1621.129326 
 
OD 140818 0.196 0.200 0.198 0.003 0.127 0.25703 257.0329893 1542.197936 
 
OS 140818 0.242 0.247 0.245 0.004 0.174 0.35114 351.1434932 2106.860959 
 
OD 102140 0.191 0.201 0.196 0.007 0.125 0.25299 252.9852257 1517.911354 
 
OS 102140 0.179 0.183 0.181 0.003 0.110 0.22263 222.6269986 1335.761991 
 
OD 112296 0.709 0.595 0.652 0.081 0.581 1.17588 1175.875329 7055.251973 
 
OS 112296 0.535 0.642 0.589 0.076 0.518 1.04736 1047.358834 6284.153005 
 
 
 
 
y = 0.4941x
R² = 0.9932
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0.0 0.5 1.0 1.5 2.0
A
b
s
Protein Conc mg/mL
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BCA Canine Samples 12-1-16 SET VI 
          
  
ABS 
1 
ABS 
2 AVG ST. DEV. Conc (mg/mL) Corrected 
  
  
1.127 1.015 1.071 0.079 2.000 0.996 
  
  
0.850 0.835 0.843 0.011 1.500 0.767 
  
  
0.620 0.618 0.619 0.001 1.000 0.544 
  
  
0.480 0.491 0.486 0.008 0.750 0.410 
  
  
0.364 0.364 0.364 0.000 0.500 0.289 
  
  
0.230 0.224 0.227 0.004 0.250 0.152 
  
  
0.146 0.145 0.146 0.001 0.125 0.070 
  
  
0.087 0.087 0.087 0.000 0.025 0.012 
  
  
0.075 0.076 0.076 0.001 0.000 0.000 
  
  
 
        
          
          
          
          
          
          
          
          
          
          
          
        
 
 
          
          
 
Sample 
ABS 
1 
ABS 
2 AVG ST DEV corrected mg/mL ug/mL 6x 
 
OD 128357 0.210 0.216 0.213 0.004 0.138 0.26756 267.5617824 1605.370695 
 
OS 128357 0.200 0.189 0.195 0.008 0.119 0.23156 231.5625608 1389.375365 
 
OD 140688 0.173 0.161 0.167 0.008 0.092 0.17805 178.0502043 1068.301226 
 
OS 140688 0.287 0.294 0.291 0.005 0.215 0.41837 418.3693326 2510.215995 
 
OD 132730 0.147 0.163 0.155 0.011 0.080 0.15470 154.6993579 928.1961471 
 
OS 132730 0.201 0.195 0.198 0.004 0.123 0.23837 238.3732244 1430.239346 
 
OD 140932 0.239 0.259 0.249 0.014 0.174 0.33761 337.6143219 2025.685931 
 
 
 
 
y = 0.5139x
R² = 0.9959
0.0
0.2
0.4
0.6
0.8
1.0
1.2
0.0 0.5 1.0 1.5 2.0
A
b
s
Protein Conc mg/mL
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APPENDIX C 
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